ORAP

This brand name is authorized in Brazil, Estonia, France, Germany, Malta, Netherlands, South Africa, Spain, Tunisia, UK.

Active ingredients

The drug ORAP contains one active pharmaceutical ingredient (API):

1	Pimozide UNII 1HIZ4DL86F - PIMOZIDE
	Pimozide is an orally active neuroleptic drug which blocks central dopaminergic receptors. Pimozide antagonises many of the actions of amphetamine and apomorphine.
	Read more about Pimozide

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
ORAP Tablet	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
N05AG02	Pimozide	N Nervous system → N05 Psycholeptics → N05A Antipsychotics → N05AG Diphenylbutylpiperidine derivatives
Discover more medicines within N05AG02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
BR	Câmara de Regulação do Mercado de Medicamentos	514502802113314
DE	Bundesinstitut für Arzneimittel und Medizinprodukte	01431877, 02424589, 03387494, 03416480, 04334672, 04964864, 06868969, 07488051, 08743019, 08875347, 08875353, 08875376, 14165561
EE	Ravimiamet	1272822, 1737053
ES	Centro de información online de medicamentos de la AEMPS	49503, 49504
FR	Base de données publique des médicaments	60625647, 62495939
GB	Medicines & Healthcare Products Regulatory Agency	36884
MT	Medicines Authority	AA1293/00101, AA565/18202, AA729/27401, AA729/27402
NL	Z-Index G-Standaard, PRK	2542, 6653
TN	Direction de la Pharmacie et du Médicament	2343021
ZA	Health Products Regulatory Authority	B/2.6.5/1017, K/2.6.5/137